Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–11 of 11 results
Advanced filters: Author: John Eikelboom Clear advanced filters

  • A new meta-analysis, which evaluated individual patient data from randomized trials of aspirin in patients with non-disabling acute brain ischaemia, found this drug to be much more efficacious at reducing early stroke recurrence than was previously estimated.

    • Robert G. Hart
    • John W. Eikelboom
    News & Views
    Nature Reviews Neurology
    Volume: 12, P: 434-435

  • Dabigatran has been associated with an increase in acute coronary events when compared with warfarin in several randomized trials, and now in a meta-analysis by Uchino and Hernandez. We critically review the evidence for this association and consider the implications for patient care.

    • John W. Eikelboom
    • Jeffrey I. Weitz
    News & Views
    Nature Reviews Cardiology
    Volume: 9, P: 260-262

  • Atrial fibrillation and chronic kidney disease (CKD) frequently coexist and confer an increased risk of stroke. Novel anticoagulants are attractive options over warfarin but undergo renal clearance to varying degrees, and therefore require special consideration in patients with CKD. Recent studies also challenge the benefits of warfarin anticoagulation for atrial fibrillation patients undergoing haemodialysis. This Review discusses the data relating to anticoagulation in patients with atrial fibrillation and CKD and highlights the need for further studies to delineate the optimal use of new anticoagulant agents in patients with CKD.

    • Robert G. Hart
    • John W. Eikelboom
    • Charles A. Herzog
    Reviews
    Nature Reviews Nephrology
    Volume: 8, P: 569-578

  • Antithrombotic therapy with ADP-receptor antagonists or anticoagulant agents improves outcomes in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. However, the current standard-of-care ADP-receptor antagonist for dual antiplatelet therapy, clopidogrel, and the currently available oral anticoagulants, the coumarins, have several limitations. In this Review, the authors discuss the pharmacology and clinical potential of new antithrombotic drugs, with an emphasis on data from phase III clinical trials.

    • Jeremy S. Paikin
    • John W. Eikelboom
    • Jack Hirsh
    Reviews
    Nature Reviews Cardiology
    Volume: 7, P: 498-509

  • Direct inhibitors of thrombin are a novel class of anticoagulant. The authors critically review the data from clinical trials on the use of the parenteral and oral forms of these drugs for primary or secondary prevention or treatment in patients with acute coronary syndrome, atrial fibrillation, or venous thromboembolism, or those undergoing percutaneous coronary intervention or orthopedic surgery.

    • Kyle A. Arsenault
    • Jack Hirsh
    • John W. Eikelboom
    Reviews
    Nature Reviews Cardiology
    Volume: 9, P: 402-414

  • Aspirin can effectively prevent arterial thrombosis; however, its efficacy is limited as it inhibits the synthesis of only one platelet agonist (thromboxane A2). Here Raju and colleagues review agents that target ADP-mediated platelet activation. They examine controversies and unresolved issues associated with clopidogrel—the optimum loading dose, duration of treatment and incomplete platelet inhibition—and the new ADP-receptor antagonists prasugrel, AZD6140 and cangrelor, and explore their potential relative to each other and to clopidogrel.

    • Nina C Raju
    • John W Eikelboom
    • Jack Hirsh
    Reviews
    Nature Clinical Practice Cardiovascular Medicine
    Volume: 5, P: 766-780

  • Inhibition of factor XI has emerged as a promising strategy to mitigate bleeding while potentially preserving antithrombotic efficacy. In this Review, the authors comprehensively discuss the rationale, pharmacology, evidence and future directions for factor XI inhibitors across various clinical settings.

    • Davide Capodanno
    • John H. Alexander
    • Dominick J. Angiolillo
    Reviews
    Nature Reviews Cardiology
    Volume: 22, P: 896-912

  • In this Review, the authors address considerations for enteral antithrombotic therapy in patients with cardiovascular disease and gastrointestinal comorbidities, who often have an increased risk of gastrointestinal bleeding. Approaches include tailoring of antithrombotic regimens and gastrointestinal-protection strategies.

    • Azita H. Talasaz
    • Parham Sadeghipour
    • Behnood Bikdeli
    Reviews
    Nature Reviews Cardiology
    Volume: 21, P: 574-592

  • Many patients with cardiovascular disease have a residual risk of ischaemic events despite receiving antiplatelet therapy. In this Review, Angiolillo and colleagues discuss the pharmacological rationale and clinical development of dual-pathway inhibition strategies for the prevention of atherothrombotic events in patients with cardiovascular disease.

    • Davide Capodanno
    • Deepak L. Bhatt
    • Dominick J. Angiolillo
    Reviews
    Nature Reviews Cardiology
    Volume: 17, P: 242-257